Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis.
Kemp
E
E
Nielsen
H
H
Petersen
L J
LJ
Gam
A N
AN
Dahlager
J
J
Horn
T
T
Larsen
S
S
Olsen
S
S
D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D005921:Glomerulonephritis / Q000139:chemically induced*; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007555:Isoxazoles / Q000009:adverse effects* / Q000627:therapeutic use; D000077339:Leflunomide; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D018124:Receptors, Tumor Necrosis Factor; D000077339:Leflunomide; D000068800:Etanercept